# A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

> **NCT07230652** · PHASE1 · RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Schizophrenia
- Alzheimer's Disease Psychosis

## Interventions

- **DRUG:** LY03020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07230652
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07230652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07230652, "A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07230652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*